Volume 19, Issue 76 (5-2011)                   J Adv Med Biomed Res 2011, 19(76): 1-10 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghamohammadi V, Pourghassem Gargari B, Aliasgharzadeh A. Evaluation of the Level of Plasma Homocysteine in Patients with Type 2 Diabetes Mellitus under Metformin Treatment and Its Correlation with Serum Total Antioxidant Capacity, Malondialdehyde, Creatinine, Insulin Resistance and Glycemic Control. J Adv Med Biomed Res 2011; 19 (76) :1-10
URL: http://journal.zums.ac.ir/article-1-1578-en.html
Evaluation of the Level of Plasma Homocysteine in Patients with Type 2 Diabetes Mellitus under Metformin Treatment and Its Correlation with Serum Total Antioxidant Capacity, Malondialdehyde, Creatinine, Insulin Resistance and Glycemic Control
Vahedeh Aghamohammadi1 , Bahram Pourghassem Gargari *2 , Aliakbar Aliasgharzadeh3
1- Nutritional Research Center, Dept. of Biochemistry & Nutrition, Faculty of Health &Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
2- Nutritional Research Center, Dept. of Biochemistry & Nutrition, Faculty of Health &Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. , pourghassemb@tbzmed.ac.ir
3- Faculty of Medicine, Endocrine and Metabolism Section, Imam Reza Teaching Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:   (191625 Views)

Background and Objective: In patients with diabetes, elevated homocysteine levels have been reported to be associated with endothelial dysfunction, insulin resistance, dyslipidemia, poor control of disease, nephropathy, macroangiopathy and oxidative stress. Thus, this observational study was performed to determine the plasma homocysteine level and its correlation with clinical, biochemical and nutritional variables.
Materials and Methods: This study was performed on 70 men with type 2 diabetes under metformin
(at least 1500 mg daily) treatment. Regarding plasma homocysteine, patients were divided into two groups: 31patients with normal homocysteine (group 1: Hcy<15 µmol/L) and 39 patients with hyperhomocysteinemia (group 2: Hcy>15 µmol/L).
Results: 55.1% patients had hyperhomocysteinemia but none of them had folate and B12 deficiency. Significant differences between the two groups, were found for serum folate, total antioxidant capacity and creatinine. No differences were found for insulin resistance and glycemic control. Multiple stepwise linear regression analysis using plasma homocysteine as a dependent variable and all other clinical and laboratory parameters as independent variables indicated that age (β=0.344), creatinine (β=0.351), vitamin B12 (β=0.235), total antioxidant capacity (β=0.285) and malondialdehyde (β=0.245) were independently associated with homocysteine concentration. No correlation was found between the homocysteine and glycemic control, HOMA-IR and intake of B vitamins and caffeine. 
Conclusion: Further studies with a large sample size are required to assess the association of plasma homocysteine with total antioxidant capacity and other biomarkers of oxidative stress in type2 diabetes.

Keywords: Homocysteine, Glycemic control, Insulin resistance, Type II Diabetes Mellitus, Total Antioxidant capacity
Full-Text [PDF 266 kb]   (162999 Downloads)    
Type of Study: Original Research Article |
Received: 2011/08/24 | Accepted: 2014/06/22 | Published: 2014/06/22
References
1. Franz JM. Medical nutrition therapy for diabetes mellitus and hyperglycemia of nondiabetic origin. In: Mahan LK, Escott-Stump S. Krause's food and nutrition therapy. Missouri: Saunders Elsevier; 2008: 764-804.
2. Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J. 2009; 15: 591-9. [DOI:10.26719/2009.15.3.591] [PMID]
3. Hunter-Lauin C, Hudson PR, Mukherjee S,
4. et al. Folate supplementation reduces serum Hsp70 level with type2 diabetes. Cell stress chaperones. 2004; 9: 344-9. [DOI:10.1379/CSC-28R.1] [PMID] [PMCID]
5. Kesavulu MM, Giri R, Kameswara Rao B, Apparao C. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications. Diabetes Meta. 2000; 26: 387-92.
6. Becker A, Kostense PJ, Bos G, et al. Hyperhomocysteinemia is associated with coronary events in type2 diabetes. J Intern Med. 2003; 253: 293-300. [DOI:10.1046/j.1365-2796.2003.01113.x] [PMID]
7. Signorello MG, Viviani GL, Armani U. Homocysteine, reactive oxygen species and nitric oxide in type 2 diabetes mellitus. Thrombosis Res. 2007; 120: 607-13. [DOI:10.1016/j.thromres.2006.11.008] [PMID]
8. Fishman EZ, Motro M, Tenenbuum A. Non insulin antidiabetic therapy in cardiac patients: current problems and future prospects. Adv cardiol.2008; 45:154-70. [DOI:10.1159/000115193] [PMID]
9. Mustafa S, Neslihan BT, Derun E, Nedret T, Nilgun D. Effects of metformin or resiglatzone on serum concentration of homocysteine, folate and vitamin B12 in patients with type 2diabetes mellitus. J Diabetes Complications. 2007; 21: 118-23. [DOI:10.1016/j.jdiacomp.2005.10.005] [PMID]
10. Krentz AJ, Bailey CJ. Oral Antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005; 65: 385-411. [DOI:10.2165/00003495-200565030-00005] [PMID]
11. Ranjbar GH, Bazarghan O, Mehdizadeh A, Zare N, Saadat N. Serum Homocysteine in patients with type 2 diabetes that use metformin and glibenclamide. Iranian J Diabetes Lipid Disorder. 2004; 2: 23-30.
12. Mashavi M, Hanah R, Boaz M, et al .Effect of homocysteine lowering therapy on arterial elasticity and metabolic parameters in metformin treated diabetic patients. Atherosclerosis. 2008; 199: 362-4. [DOI:10.1016/j.atherosclerosis.2007.11.037] [PMID]
13. Pongchaidecha M, Srikausalanukul V, Chattananon A, Tanjariyapons. Effect of metformin on plasma homocysteine, vitamin B12, folic acid: a cross-sectional study in Patients with type 2 diabetes mellitus. J med Assos Thai. 2004; 87: 780-7.
14. Daniel SL. Abnormal methyl metabolism in pancreatic toxicity and diabetes. J Nutr. 2002; 2373-76. [DOI:10.1093/jn/132.8.2373S] [PMID]
15. Gjin N, Adnan K, Seigmund B, et al. Circulating homocysteine levels in patients with T2D. Nutr Metab Cardiovasc Dis. 2008; 16: 66-73. [DOI:10.1016/j.numecd.2006.03.007] [PMID]
16. Meigs JB, Jacques PF, Selhub J, et al. Framingham offspring study. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care. 2001; 24: 1403-10. [DOI:10.2337/diacare.24.8.1403] [PMID]
17. Victor SM, Migel V, Francisco JR, Felix G, Joaguin M, Raimundo G. Elevated plasma homocysteine levels in hyperinsulinemic obese subjects. J Nutr Biochem.2002; 13:75-9. [DOI:10.1016/S0955-2863(01)00197-8]
18. Yumi M, Akira K, Akatuski K, Masoa Y, Nobuki F, Yutaka T. Factors associated with serum total homocysteine level in type 2 diabetes. Environ Health Prev Med. 2008; 13:148-55. [DOI:10.1007/s12199-008-0024-2] [PMID] [PMCID]
19. Jacobs RL, House JD, Brosnan ME, Brosnan JT. Effects of streptozotocin - induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes. 1998; 47: 1967-70. [DOI:10.2337/diabetes.47.12.1967] [PMID]
20. Agullo- Ortuno MT, Albaladejo MD, Parra S. Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta. 2002; 326:105-12. [DOI:10.1016/S0009-8981(02)00287-5]
21. Mattews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985; 28: 412-9. [DOI:10.1007/BF00280883] [PMID]
22. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1967; 16: 31-41. [DOI:10.1159/000180580] [PMID]
23. Russo GT, Benedetto AD, Giorda C, et al. Correlates of total homocysteine plasma concentration in type 2 diabetes. Eur J Clin Invest. 2004; 34: 197-204. [DOI:10.1111/j.1365-2362.2004.01319.x] [PMID]
24. Iris F, Benzie F, Strain S. The ferric reducing antioxidant assay. Methods Enzymol.1999; 292:15-27. [DOI:10.1016/S0076-6879(99)99005-5]
25. Janero D. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1998; 9: 515-40. [DOI:10.1016/0891-5849(90)90131-2]
26. Vinicius D, Areuza V, Altair JM, Decio SB , Rosana AM, Teimi M. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutrotion. 2007; 23: 242-7. [DOI:10.1016/j.nut.2007.01.002] [PMID]
27. Ilhan T, Berrin C, Zeynep C, PinarT, Aysen A, Bakir K. Homocysteine concentration in type2 diabetic patients with silent myocardial ischemia. J Diabetes Complications. 2004; 18:165-8. [DOI:10.1016/j.jdiacomp.2003.12.002] [PMID]
28. Fakhrzadeh H, Ghotbi S, Pouebrahim R, et al. Total plasma homocysteine, folateand vitamin B12 status in healthy Iranian adults: the Tehran homocysteine survey (2003-2004)/a cross-sectional population based study. BMC Public Health. 2006; 6: 29. [DOI:10.1186/1471-2458-6-29] [PMID] [PMCID]
29. Aarsand AK, Carlsen SM. Folate administration reduces circulating homocysteine levels in NIDDM patients on long term metformin treatment. J Inern Med. 1998; 244: 169-74. [DOI:10.1046/j.1365-2796.1998.00361.x] [PMID]
30. Callaghan TS, Hadden DR, Tomkin GH. Megaloblastic anemia due to vitamin B12 malabsorption associated with long term metformin treatment. Br Med J. 1980; 17: 1214-15. [DOI:10.1136/bmj.280.6225.1214] [PMID] [PMCID]
31. Stein JH, Bride P. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening and treatment. Arch Intern Med. 1998; 158: 1301-06. [DOI:10.1001/archinte.158.12.1301] [PMID]
32. Moat SJ, Hill MH, Mcdowell IFW, et al. Reduction in plasma total homocysteine through increasing folate intake in healthy individuals is not associated with changes in measures of antioxidant activity or oxidant damage. Eur J Clin Nutr. 2003; 57: 483-9. [DOI:10.1038/sj.ejcn.1601554] [PMID]
33. Ozmen B, Ozmen D, Turgan N, Habif S, Mutaf I, Bayindir O. Association between homocysteine and renal function in patients with type 2diabetes. Ann Clin Lab Sci. 2002; 32:279-86.
34. Mudd Sh, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism. 1975; 24: 721-35. [DOI:10.1016/0026-0495(75)90040-2]
35. Elias AN, Eng S. Homocysteine concentrations in patients with diabetes mellitus-relationship to microvascular and macrovascular disease. Diabetes Obes Metab. 2005; 7: 117-21. [DOI:10.1111/j.1463-1326.2004.00376.x] [PMID]
36. Melissa S, Wei-hsun Ch, Savitri KK, et al. Total homocysteine, Diet, and lipid profiles in type1 and type2 diabetic and non diabetic adolescents. J Cardiovasc Nurs. 2006; 21: 47-55. [DOI:10.1097/00005082-200601000-00010]
37. Danvahi R, Falkner B. Relationship of homocysteine with cardiovascular disease and blood pressure. J Clin Hypertens. 2004; 6: 494-8. [DOI:10.1111/j.1524-6175.2004.03643.x] [PMID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb